Previous 10 | Next 10 |
TrovaGene (NASDAQ: TROV ) +56% on positive response to treatment in phase 1b/2 trial of onvansertib in patients with KRAS-mutated metastatic colorectal cancer. More news on: TrovaGene, Inc., Biogen Inc., Stamps.com Inc., Stocks on the move, Read more ...
~ Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~ ~ Biorphen Eliminates Need for Compounding, Reducing Risks for Unsafe Injection Practices, Medication Administration Errors, Sterility Breaches, and Waste ~ DEER PARK, Ill.,...
MKM partners initiates coverage on seven pot stocks: Curaleaf Holdings ( OTCPK:CURLF ): Sell, Aurora Cannabis (NYSE: ACB ): Sell ( -1% ), Canopy Growth (NYSE: CGC ): Neutral (up a fraction), Tilray (NASDAQ: TLRY ): Neutral (up a fraction), Cronos Group (NASDAQ: CRON ): Neutral ( +1% ), ...
DEER PARK, Ill., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will participate in the Lake S...
ET-104 Successfully Demonstrated Bioequivalence to Currently Approved Oral Solid Formulation New Drug Application (NDA) Submission Expected in Fourth Quarter of 2019 Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commerciali...
Eton Pharmaceuticals, Inc. (ETON) Q2 2019 Earnings Conference Call August 6, 2019 4:30 p.m. ET Company Participants David Krempa - VP, Business Development Sean Brynjelsen - CEO Wilson Troutman - CFO Conference Call Participants Ram Selvaraju - H.C. Wainwright Presentati...
The following slide deck was published by Eton Pharmaceuticals, Inc. in conjunction with this Read more ...
Eton Pharmaceuticals (NASDAQ: ETON ): Q2 GAAP EPS of -$0.18 beats by $0.10 . More news on: Eton Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
ET-203 NDA submitted, Three Additional Product Submissions Expected in 2019 ET-105 Acquisition Closed & Application Assigned PDUFA Date of March 17, 2020 Company to Host Conference Call and Webcast Today at 4:30p.m. ET (3:30 p.m. CT) DEER PARK, Ill., Aug. 06, 2019 (GLOBE NE...
NASHVILLE, Tenn., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that its newly formed subsidiary, Stowe Pharmaceuticals, Inc., has entered into an agreement with TGV Health to acquire worldwide rights to the Zian™ anti-microbial molecule fo...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...